ATAI Life Sciences N.V. (NASDAQ: ATAI)
$1.2350
+0.0450 ( +3.78% ) 756.7K
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Market Data
Open
$1.2350
Previous close
$1.1900
Volume
756.7K
Market cap
$197.17M
Day range
$1.1550 - $1.2350
52 week range
$1.0300 - $2.8500
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 51 | Jun 05, 2024 |
| 3 | Insider transactions | 2 | Jun 04, 2024 |
| 3 | Insider transactions | 2 | Jun 04, 2024 |
| 8-k | 8K-related | 15 | May 23, 2024 |
| 4 | Insider transactions | 1 | May 20, 2024 |
| 10-q | Quarterly Reports | 101 | May 15, 2024 |
| 8-k | 8K-related | 17 | May 15, 2024 |
| 4 | Insider transactions | 1 | May 03, 2024 |
| def | Proxies and info statements | 6 | Apr 22, 2024 |
| 4 | Insider transactions | 1 | Apr 17, 2024 |